CorMedix(CRMD) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, net revenue reached $128.6 million, a significant increase from $31.2 million in Q4 2024, primarily driven by DefenCath's contribution of $91.2 million and Melinta's contribution of $37.4 million [16][17] - For the full year 2025, total revenue on a pro forma basis was $401.3 million, aligning with previously established guidance [16] - The company reported a net income of $14 million in Q4 2025, impacted by a tax expense of $42.4 million, mostly non-cash [18][19] - Adjusted EBITDA for Q4 was $77.2 million, reflecting modest growth quarter-over-quarter [19][20] - Cash and cash equivalents at the end of Q4 were $148.5 million, supported by strong operating cash flow of nearly $100 million during the quarter [20] Business Line Data and Key Metrics Changes - DefenCath generated $258.8 million in net sales for the full year 2025, with peak sales of just under $260 million achieved [5][16] - The Melinta portfolio contributed $37.4 million in Q4 2025, marking its first full reporting period post-acquisition [16] Market Data and Key Metrics Changes - The company anticipates a revenue concentration for DefenCath to be front-loaded in the first half of 2026, with expected price erosion in the latter half due to the transition to a bundled add-on reimbursement mechanism [6][7] - The estimated market opportunity for REZZAYO is approximately $2.5 billion across its indications, while DefenCath and TPN are estimated between $500 million and $750 million [9] Company Strategy and Development Direction - The company is focused on maintaining patient utilization rates for DefenCath and negotiating pricing structures for 2026 and 2027 [6][7] - The acquisition of Melinta Therapeutics is seen as a strategic move to enhance growth, with a focus on integrating operations and achieving synergies [5][10] - The company is actively pursuing discussions with Medicare Advantage providers and new customers for DefenCath [8] Management's Comments on Operating Environment and Future Outlook - Management views 2025 as a transformational year and expects 2026 to be transitional, setting the stage for long-term sustainable growth [21] - The company remains confident in its financial flexibility and commercial momentum, positioning itself for both organic and inorganic growth opportunities [21] Other Important Information - The company completed its first analyst R&D day, focusing on educating stakeholders about the market opportunity for REZZAYO and its pipeline assets [8][9] - The phase 3 ReSPECT study for REZZAYO is on track for top-line data release in Q2 2026 [11][12] Q&A Session Summary Question: Update on dialysis customer conversations regarding DefenCath pricing - Management indicated that conversations are progressing well, focusing on preserving patient utilization and negotiating pricing structures for 2027 [23] Question: Clinical significance of REZZAYO phase 3 data - Management highlighted the importance of pathogen data and secondary endpoints in guiding commercial utility and marketing strategies [24][25] Question: Developments on TDAPA extension bills - Management noted that timing is uncertain due to legislative complexities and current global events, but they are actively working on the issue [29][30] Question: Inpatient opportunity with DefenCath and Melinta product portfolio - Management discussed the current customer mix and potential growth opportunities, emphasizing the importance of onboarding new customers [33][41]